# Solid Biosciences Inc. (SLDB)

Source: https://www.quantisnow.com/company/SLDB
Generated: 2026-11-08T17:11:07.974Z

- Ticker: SLDB
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Biological Products (No Diagnostic Substances)
- IPO year: 2018
- SEC CIK: 0001707502
- Website: solidbio.com

## About

Solid Biosciences Inc., a life science company, engages in developing therapies for duchenne muscular dystrophy (DMD) in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles. Its portfolio also comprises Anti-LTBP4, a complementary disease modifying program that identifies and develops a monoclonal antibody intended to reduce fibrosis and inflammation by targeting and stabilizing the LTBP4 protein. In addition, the company engages in developing biomarkers and sensors; and Solid Suit program that includes the development of wearable assistive devices that focus on providing functional and therapeutic benefits. Solid Biosciences Inc. has strategic collaboration with Ultragenyx to develop and commercialize new gene therapies for Duchenne Muscular Dystrophy. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.

## Latest SLDB news and filings

- 2026-11-06 21:23 UTC [SEC Schedule 13D] [Amendment: SEC Form SCHEDULE 13D/A filed by Solid Biosciences Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13da-filed-by-solid-biosciences-inc-6779155)
- 2026-11-05 13:00 UTC [Conference Announcement] [Solid Biosciences to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference](https://www.quantisnow.com/insight/solid-biosciences-to-participate-in-the-guggenheim-3rd-annual-healthcare-6774831)
- 2026-11-04 21:07 UTC [Earnings] [Solid Biosciences Reports Third Quarter 2026 Financial Results and Provides Business Updates](https://www.quantisnow.com/insight/solid-biosciences-reports-third-quarter-2026-financial-results-and-provides-6772476)
- 2026-11-04 21:02 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Solid Biosciences Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-solid-biosciences-inc-6772219)
- 2026-10-26 20:05 UTC [SEC Form 4] [SEC Form 4 filed by Solid Biosciences Inc.](https://www.quantisnow.com/insight/sec-form-4-filed-by-solid-biosciences-inc-6757559)
- 2026-10-26 12:00 UTC [Solid Biosciences Announces European Commission Orphan Designation for SGT-212 and Continued Progress in the FALCON Trial in Friedreich’s Ataxia](https://www.quantisnow.com/insight/solid-biosciences-announces-european-commission-orphan-designation-for-sgt-212-and-6757037)
- 2026-10-20 20:05 UTC [SEC Form 4] [Chief Medical Officer Brooks Gabriel sold $24,582 worth of shares (4,374 units at $5.62) as part of a pre-agreed trading plan (SEC Form 4)](https://www.quantisnow.com/insight/chief-medical-officer-brooks-gabriel-sold-24582-worth-of-shares-6752104)
- 2026-10-20 12:00 UTC [Solid Biosciences to Present Research Across Gene Therapy Development, Delivery and Manufacturing at ESGCT 2026](https://www.quantisnow.com/insight/solid-biosciences-to-present-research-across-gene-therapy-development-delivery-6751492)
- 2026-10-15 12:58 UTC [Analyst Coverage Initiated] [UBS initiated coverage on Solid Biosciences with a new price target](https://www.quantisnow.com/insight/ubs-initiated-coverage-on-solid-biosciences-with-a-new-price-6747524)
- 2026-10-06 20:35 UTC [SEC Form 4] [SEC Form 4 filed by Solid Biosciences Inc.](https://www.quantisnow.com/insight/sec-form-4-filed-by-solid-biosciences-inc-6739167)
- 2026-10-01 20:05 UTC [Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://www.quantisnow.com/insight/solid-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-6732324)
- 2026-09-16 12:15 UTC [Analyst Coverage Initiated] [RBC Capital Mkts initiated coverage on Solid Biosciences with a new price target](https://www.quantisnow.com/insight/rbc-capital-mkts-initiated-coverage-on-solid-biosciences-with-a-6717013)
- 2026-09-02 12:00 UTC [Solid Biosciences to Participate at Upcoming Investor Conferences](https://www.quantisnow.com/insight/solid-biosciences-to-participate-at-upcoming-investor-conferences-6702335)
- 2026-08-21 11:50 UTC [Analyst Coverage Resumed] [Truist resumed coverage on Solid Biosciences with a new price target](https://www.quantisnow.com/insight/truist-resumed-coverage-on-solid-biosciences-with-a-new-price-6690749)
- 2026-08-14 21:22 UTC [Amendment: SEC Form SCHEDULE 13D/A filed by Solid Biosciences Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13da-filed-by-solid-biosciences-inc-6683742)
- 2026-08-06 21:15 UTC [SEC Form 8-K] [SEC Form 8-K filed by Solid Biosciences Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-solid-biosciences-inc-6670014)
- 2026-08-06 21:07 UTC [SEC Form 424B5] [SEC Form 424B5 filed by Solid Biosciences Inc.](https://www.quantisnow.com/insight/sec-form-424b5-filed-by-solid-biosciences-inc-6669944)
- 2026-08-06 21:00 UTC [SEC Form S-3ASR] [SEC Form S-3ASR filed by Solid Biosciences Inc.](https://www.quantisnow.com/insight/sec-form-s-3asr-filed-by-solid-biosciences-inc-6669877)
- 2026-08-06 20:08 UTC [Solid Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Updates](https://www.quantisnow.com/insight/solid-biosciences-reports-second-quarter-2026-financial-results-and-provides-6668953)
- 2026-08-06 20:04 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Solid Biosciences Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-solid-biosciences-inc-6668648)
- 2026-08-06 14:41 UTC [SEC Form SCHEDULE 13G filed by Solid Biosciences Inc.](https://www.quantisnow.com/insight/sec-form-schedule-13g-filed-by-solid-biosciences-inc-6668129)
- 2026-07-07 20:05 UTC [SEC Form 4] [Director Smith Ian F converted options into 3,440 shares, increasing direct ownership by 3% to 138,145 units (SEC Form 4)](https://www.quantisnow.com/insight/director-smith-ian-f-converted-options-into-3440-shares-increasing-6630027)
- 2026-06-24 22:50 UTC [SEC Form 3] [New insider Ra Capital Management, L.P. claimed ownership of 12,036,126 shares (SEC Form 3)](https://www.quantisnow.com/insight/new-insider-ra-capital-management-lp-claimed-ownership-of-12036126-6614749)
- 2026-06-24 22:49 UTC [Amendment: SEC Form SCHEDULE 13D/A filed by Solid Biosciences Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13da-filed-by-solid-biosciences-inc-6614746)
- 2026-06-11 20:05 UTC [SEC Form 4] [SEC Form 4 filed by Director Stone Adam Leo](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-stone-adam-leo-6598854)
- 2026-06-10 20:05 UTC [SEC Form 8-K] [Solid Biosciences Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders](https://www.quantisnow.com/insight/solid-biosciences-inc-filed-sec-form-8-k-submission-of-matters-6597028)
- 2026-06-05 20:03 UTC [SEC Form 424B7 filed by Solid Biosciences Inc.](https://www.quantisnow.com/insight/sec-form-424b7-filed-by-solid-biosciences-inc-6591102)
- 2026-06-01 20:05 UTC [Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://www.quantisnow.com/insight/solid-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-6581494)
- 2026-06-01 12:00 UTC [Solid Biosciences to Participate at Upcoming Investor Conferences](https://www.quantisnow.com/insight/solid-biosciences-to-participate-at-upcoming-investor-conferences-6580692)
- 2026-05-12 20:08 UTC [Solid Biosciences Reports First Quarter 2026 Financial Results and Provides Business Updates](https://www.quantisnow.com/insight/solid-biosciences-reports-first-quarter-2026-financial-results-and-provides-6548001)
- 2026-05-12 20:02 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Solid Biosciences Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-solid-biosciences-inc-6547791)
- 2026-05-07 12:00 UTC [Solid Biosciences Doses First Participant in Phase 3 IMPACT DUCHENNE Clinical Trial Evaluating SGT-003 in Duchenne Muscular Dystrophy](https://www.quantisnow.com/insight/solid-biosciences-doses-first-participant-in-phase-3-impact-duchenne-6537597)
- 2026-05-05 13:42 UTC [Amendment: SEC Form SCHEDULE 13G/A filed by Solid Biosciences Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-solid-biosciences-inc-6531221)
- 2026-05-01 20:05 UTC [Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://www.quantisnow.com/insight/solid-biosciences-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-6526664)
- 2026-04-30 12:00 UTC [Solid Biosciences to Showcase a Large Presence at the 29th Annual Meeting of the American Society of Gene and Cell Therapy](https://www.quantisnow.com/insight/solid-biosciences-to-showcase-a-large-presence-at-the-29th-6522924)
- 2026-04-28 12:00 UTC [Solid Biosciences Announces Receipt of European Commission Orphan Drug Designation for SGT-003 for the Treatment of Duchenne Muscular Dystrophy](https://www.quantisnow.com/insight/solid-biosciences-announces-receipt-of-european-commission-orphan-drug-designation-6517686)
- 2026-04-23 20:07 UTC [SEC Form DEFA14A] [SEC Form DEFA14A filed by Solid Biosciences Inc.](https://www.quantisnow.com/insight/sec-form-defa14a-filed-by-solid-biosciences-inc-6512494)
- 2026-04-23 20:03 UTC [SEC Form DEF 14A] [SEC Form DEF 14A filed by Solid Biosciences Inc.](https://www.quantisnow.com/insight/sec-form-def-14a-filed-by-solid-biosciences-inc-6512325)
- 2026-04-21 20:05 UTC [SEC Form 4] [SEC Form 4 filed by Tan Kevin](https://www.quantisnow.com/insight/sec-form-4-filed-by-tan-kevin-6508378)
- 2026-04-21 20:05 UTC [SEC Form 4] [SEC Form 4 filed by Herzich Paul](https://www.quantisnow.com/insight/sec-form-4-filed-by-herzich-paul-6508377)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/SLDB
- Earnings history: https://www.quantisnow.com/earnings/SLDB
- Dividend history: https://www.quantisnow.com/dividends/SLDB
- Insider transactions: https://www.quantisnow.com/insiders/SLDB
- Options chain: https://www.quantisnow.com/options/SLDB
- SEC 8-K filings only: https://www.quantisnow.com/company/SLDB/8-k
- RSS and alerts for SLDB: https://www.quantisnow.com/docs/rss-feeds.md